T1	intervention 53 63	exemestane
T3	total-participants 324 327	195
T5	total-participants 489 492	191
T6	intervention-participants 549 551	96
T7	control 656 669	control group
T8	control-participants 675 677	95
T9	outcome 976 990	effective rate
T10	iv-bin-percent 995 1000	44.8%
T11	cv-bin-percent 1024 1029	45.3%
T12	outcome 1068 1086	level of estradiol
T17	outcome 1582 1588	thirst
T18	outcome 1590 1599	giddiness
T19	outcome 1605 1611	nausea
T2	eligibility 328 390	patients with postmenopausal advanced metastatic breast cancer
T4	iv-cont-mean 1091 1095	5.17
T13	iv-cont-sd 1100 1117	6.68 x 10(4) pg/L
T14	cv-cont-mean 1122 1126	4.19
T20	cv-cont-sd 1131 1148	3.06 x 10(4) pg/L
T16	iv-cont-mean 1208 1212	3.08
T21	iv-cont-sd 1217 1234	2.80 x 10(4) pg/L
T22	cv-cont-mean 1239 1243	2.76
T23	cv-cont-sd 1248 1265	1.98 x 10(4) pg/L
